Dr. Langmuir Discusses Vandetanib Clinical Trials

Video

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Related Content
Jameel Muzaffar, MD

Tivumecirnon Plus Pembrolizumab Shows Activity in Checkpoint Inhibitor–Exposed Recurrent/Metastatic HNSCC

April 21st 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

FDA Grants Fast Track Designation to LYT-200 in Recurrent/Metastatic HNSCC

April 11th 2024
Article
Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

September 2nd 2021
Podcast
Deborah J. Wong, MD, PhD, HS associate clinical professor of medicine at the University of California Los Angeles School of Medicine

Atezolizumab Fails to Improve Survival Outcomes After Definitive Local Therapy in High-Risk HNSCC

April 8th 2024
Article
Michael Schickler, PhD, head, Clinical and Regulatory Affairs, Purple Biotech

NT219 Plus Cetuximab Demonstrates Efficacy, Tolerability in SCCHN

March 20th 2024
Article